These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28520234)

  • 21. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
    Suezawa M; Dainichi T; Kaku Y; Izumi M; Kataoka K; Ishii N; Koga H; Izumi K; Nishie W
    J Dermatol; 2021 Oct; 48(10):1584-1587. PubMed ID: 34265108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
    Douros A; Rouette J; Yin H; Yu OHY; Filion KB; Azoulay L
    Diabetes Care; 2019 Aug; 42(8):1496-1503. PubMed ID: 31182489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
    Shalmon D; Bar-Ilan E; Peled A; Geller S; Bar J; Schwartz N; Sprecher E; Pavlovsky M
    Acta Derm Venereol; 2024 Apr; 104():adv26663. PubMed ID: 38576104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid.
    Leisti P; Pankakoski A; Jokelainen J; Huilaja L; Panelius J; Tasanen K; Varpuluoma O
    Acta Derm Venereol; 2024 Sep; 104():adv40645. PubMed ID: 39233614
    [No Abstract]   [Full Text] [Related]  

  • 31. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
    Lee SG; Lee HJ; Yoon MS; Kim DH
    JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linagliptin-associated bullous pemphigoid treated with rituximab.
    Mani H; Safo P; Onitilo AA
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
    Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
    J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
    Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
    Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
    [No Abstract]   [Full Text] [Related]  

  • 36. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
    Kridin K
    Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.
    Armanious M; AbuHilal M
    J Cutan Med Surg; 2021; 25(2):163-168. PubMed ID: 33176433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitor-associated cutaneous eruptions: a retrospective observational study.
    Duraisamy P; Jagadeesan S; Eapen M; Thomas J
    Clin Exp Dermatol; 2022 Jul; 47(7):1283-1290. PubMed ID: 35187695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
    Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
    Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.